-+ 0.00%
-+ 0.00%
-+ 0.00%

Voyager Unveils Preclinical Data On Dual Tau Programs For Alzheimer's Ahead Of AD/PD 2025

Benzinga·03/31/2025 11:24:03
Listen to the news

- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study -

- Preclinical murine data strengthen case for specifically targeting pathologic forms of tau with the clinical-stage anti-tau antibody VY7523 -

- Voyager to host live webcast on April 7 recapping key AD/PD™ 2025 data -